Sweden
# |
Name |
EBT Margin |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
44.88%
|
Dec. 31, 2023 | USD 17.87 | 3.09% |
|
Sweden |
|
2 |
36.16%
|
Dec. 31, 2023 | USD 9.75 | -0.95% |
|
Sweden |
|
3 |
34.66%
|
Dec. 31, 2023 | USD 2.09 | -2.04% |
|
Sweden |
|
4 |
24.25%
|
Dec. 31, 2023 | USD 18.76 | 3.89% |
|
Sweden |
|
5 |
21.09%
|
Dec. 31, 2023 | USD 4.99 | 0.68% |
|
Sweden |
|
6 |
16.27%
|
Dec. 31, 2023 | USD 11.98 | -2.51% |
|
Sweden |
|
7 |
15.82%
|
Dec. 31, 2023 | USD 42.37 | 0.78% |
|
Sweden |
|
8 |
13.35%
|
Dec. 31, 2023 | USD 28.64 | 0.87% |
|
Sweden |
|
9 |
10.77%
|
Dec. 31, 2023 | USD 20.58 | 0.68% |
|
Sweden |
|
10 |
10.50%
|
Dec. 31, 2023 | USD 16.63 | 0.49% |
|
Sweden |
|
11 |
10.34%
|
Dec. 31, 2023 | USD 2.57 | -0.02% |
|
Sweden |
|
12 |
9.21%
|
April 30, 2024 | USD 5.39 | -0.39% |
|
Sweden |
|
13 |
8.85%
|
Dec. 31, 2023 | USD 3.31 | 2.33% |
|
Sweden |
|
14 |
5.86%
|
Dec. 31, 2023 | USD 3.41 | 3.24% |
|
Sweden |
|
15 |
5.80%
|
April 30, 2024 | USD 1.60 | -0.43% |
|
Sweden |
|
16 |
5.27%
|
Dec. 31, 2023 | USD 0.89 | 14.73% |
|
Sweden |
|
17 |
3.50%
|
Dec. 31, 2023 | USD 12.08 | 1.50% |
|
Sweden |
|
18 |
2.77%
|
Dec. 31, 2023 | USD 31.10 | 0.68% |
|
Sweden |
|
19 |
2.66%
|
Dec. 31, 2023 | USD 32.97 | -0.61% |
|
Sweden |
|
20 |
-0.87%
|
Dec. 31, 2023 | USD 0.14 | 1.34% |
|
Sweden |
|
21 |
-7.23%
|
Dec. 31, 2023 | USD 0.84 | -0.17% |
|
Sweden |
|
22 |
-9.66%
|
Dec. 31, 2023 | USD 0.25 | 0.32% |
|
Sweden |
|
23 |
-11.89%
|
Dec. 31, 2023 | USD 0.09 | 1.68% |
|
Sweden |
|
24 |
-21.09%
|
Dec. 31, 2023 | USD 1.88 | 0.68% |
|
Sweden |
|
25 |
-32.13%
|
Dec. 31, 2023 | USD 10.16 | -0.20% |
|
Sweden |
|
26 |
-35.63%
|
Dec. 31, 2023 | USD 0.43 | -0.78% |
|
Sweden |
|
27 |
-41.84%
|
Aug. 31, 2024 | USD 0.30 | -1.39% |
|
Sweden |
|
28 |
-44.07%
|
Dec. 31, 2023 | USD 0.61 | 0.68% |
|
Sweden |
|
29 |
-72.14%
|
Dec. 31, 2023 | USD 3.19 | 2.10% |
|
Sweden |
|
30 |
-84.54%
|
Dec. 31, 2023 | USD 0.18 | 4.90% |
|
Sweden |
|
31 |
-97.67%
|
Dec. 31, 2023 | USD 0.15 | -2.28% |
|
Sweden |
|
32 |
-105.69%
|
Dec. 31, 2023 | USD 18.25 | 2.79% |
|
Sweden |
|
33 |
-108.94%
|
April 30, 2024 | USD 0.47 | -0.26% |
|
Sweden |
|
34 |
-116.49%
|
Dec. 31, 2023 | USD 1.01 | 1.76% |
|
Sweden |
|
35 |
-146.02%
|
Dec. 31, 2023 | USD 0.23 | 11.53% |
|
Sweden |
|
36 |
-161.97%
|
Dec. 31, 2023 | USD 0.94 | 2.12% |
|
Sweden |
|
37 |
-260.89%
|
Dec. 31, 2023 | USD 0.20 | 2.06% |
|
Sweden |
|
38 |
-356.72%
|
Dec. 31, 2023 | USD 0.71 | -2.02% |
|
Sweden |
|
39 |
-393.45%
|
Aug. 31, 2024 | USD 0.22 | -6.29% |
|
Sweden |
|
40 |
-422.44%
|
Dec. 31, 2023 | USD 0.11 | 1.51% |
|
Sweden |
|
41 |
-461.93%
|
Dec. 31, 2023 | USD 2.74 | 1.67% |
|
Sweden |
|
42 |
-567.36%
|
Dec. 31, 2023 | USD 0.52 | 0.51% |
|
Sweden |
|
43 |
-619.57%
|
Dec. 31, 2023 | USD 2.91 | -2.20% |
|
Sweden |
|
44 |
-643.30%
|
Dec. 31, 2023 | USD 0.21 | 0.68% |
|
Sweden |
|
45 |
-705.41%
|
Dec. 31, 2023 | USD 0.12 | -10.06% |
|
Sweden |
|
46 |
-747.38%
|
Dec. 31, 2023 | USD 0.13 | -10.15% |
|
Sweden |
|
47 |
-861.65%
|
Dec. 31, 2023 | USD 0.39 | -0.45% |
|
Sweden |
|
48 |
-919.76%
|
Dec. 31, 2023 | USD 1.01 | -1.50% |
|
Sweden |
|
49 |
-977.58%
|
Dec. 31, 2023 | USD 0.28 | -7.61% |
|
Sweden |
|
50 |
-1,046.06%
|
Dec. 31, 2023 | USD 0.27 | 3.36% |
|
Sweden |
The Biotechnology company in Sweden with the highest EBT Margin is BioArctic AB (publ) (Stockholm Stock Exchange: BIOA-B.ST) at 44.88%.
The Biotechnology company in Sweden with the lowest EBT Margin is OncoZenge AB (publ) (Stockholm Stock Exchange: ONCOZ.ST) at -530,066.67%.
The top 10 Biotechnology companies in Sweden by EBT Margin are BioArctic AB (publ), BioGaia AB (publ), Genovis AB (publ.), CellaVision AB (publ), I-Tech AB, Biotage AB (publ), Xvivo Perfusion AB (publ), Swedish Orphan Biovitrum AB (publ), RaySearch Laboratories AB (publ) and Getinge AB (publ).
The bottom 10 Biotechnology companies in Sweden by EBT Margin are OncoZenge AB (publ), Infant Bacterial Therapeutics AB (publ), Diamyd Medical AB (publ), Lipum AB (publ), Qlife Holding AB (publ), SpectraCure AB (publ), Kancera AB (publ), Alzinova AB (publ), Nanologica AB (publ) and Isofol Medical AB (publ).